Numab Therapeutics
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Bachtobelstrasse 5, Horgen, Zurich, 8810...Website
www.numab.comRevenue
$17.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Numab Therapeutics
Founded in 2011, Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, the company is writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With the company's proprietary MATCHTM technology platform, the company is fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Numab Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Numab Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Numab Therapeutics has new funding data
Product Launch: Get notified when Numab Therapeutics launches new products
Click to see if Numab Therapeutics had a recent Job posting/layoffs
Check out if Numab Therapeutics is spiking on competitors!
Earning: See what the market has to say on Numab Therapeutics recently announced quarterly report
Numab Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Numab Therapeutics
Recommended Actions
Find VP level buyers at Numab Therapeutics
Find 2 more new buyers
Company Profile Activity
Activity Insights
Numab Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Numab Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Numab Therapeutics.
Numab Therapeutics financials insights
Gather financial insights about Numab Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$22.7M
2025
Series C
$165M
Numab Therapeutics Tech Stack
A closer look at the technologies used by Numab Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
, according to an internal source in product development, is in the midst of initiatives related to quality assurance.
Quality Assurance, Product Development, Product Management
Project
, according to an internal source in product development, began leveraging GitHub Copilot within the last six to twelve months. Numab Therapeutics is leveraging this solution for natural language interfaces.
Product Development, Product Management, Language
Project
, according to an internal source in product development, began leveraging ChatGPT within the last six to twelve months. Numab Therapeutics is leveraging this solution for natural language interfaces.
Product Development, Product Management, Language
New Hire
Executive Move
Executive Moves, New Hire
Numab Therapeutics News & Media
Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)
Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinic Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinicNumab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim
Numab to receive first milestone paymentNumab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced that David Urech, Ph.D., Chief Executive Officer and co-founder of Numab, will transition from his position as CEO and continue as a member of the Board of Directors and Chair of the R&D Committee. As part of the planned leadership transition, Numab has appointed industry veteranBaker McKenzie advises Numab Therapeutics in CHF 50 Million Series C Top-Up Financing Round
The proceeds from the financing will be used to accelerate and further advance Numab’s pipeline of clinical and pre-clinical multi-specific ...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Numab Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2011, Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, the company is writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With the company's proprietary MATCHTM technology platform, t... Read More
